MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.

MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.

Even though anti-interferon beta (IFNβ) antibodies are the main determinants of IFNβ bioactivity loss and Myxovirus-resistance protein A (MxA) is the most established marker of IFNβ biological activity in IFNβ-treated multiple sclerosis patients, their usefulness in the routine clinical practice is...

Full description

Bibliographic Details
Main Authors: Federico Serana, Luisa Imberti, Maria Pia Amato, Giancarlo Comi, Claudio Gasperini, Angelo Ghezzi, Vittorio Martinelli, Leandro Provinciali, Maria Rosa Rottoli, Stefano Sotgiu, Sergio Stecchi, Michele Vecchio, Mauro Zaffaroni, Cinzia Cordioli, Ruggero Capra
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3986392?pdf=render

Internet

http://europepmc.org/articles/PMC3986392?pdf=render

Similar Items